Thermogenesis (THMO) Leads the PRISM Pack, Up 27% For the Day

Thermogenesis Holdings (THMO) surged 27% today, leading all of the stocks being tracked by PRISM indexes.

Thermogenesis develops and commercializes automated cell processing technologies in the gene therapy field and is currently housed in the PRISM Medical Diagnostics Index, which is practically even for the day.

THMO has had a strong trading week, but has a long way to go, as the stock is down almost 94% since PRISM began tracking the stock in January of 2020.

About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit:


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Thermogenesis (THMO) Leads the PRISM Pack, Up 27% For the Day

Prism MarketView